China Feihe: low industry visibility in 2026, Neutral maintained; new products and overseas expansion are key incremental catalysts

Overview

This report is a summary of Goldman Sachs’ management meeting takeaways for China Feihe. The core focus is on 2026 operating guidance, the industry’s low birth-rate backdrop, competitive strategy, new-product momentum, and overseas expansion. The analyst maintains a Neutral rating, with a 12-month target price of HK$4.0, based on a 12.0x 2027E P/E multiple discounted to YE 2026.

Core views

Management remains cautious on 2026 because newborn visibility remains low, even though 2025 marriage registrations rose 10.8% year-on-year and birth recovery is not yet clear. At the same time, physical mom-and-baby channel offline stores may continue to contract as store closures continue. The company will use premium new products Jicui/Qicui, product mix upgrade, and online plus omnichannel transformation to offset offline channel pressure, while continuing to invest in domestic sales and marketing, and overseas localization and channel development.

Analysis framework

The report is based on post-earnings management communication, company operating guidance, Goldman Sachs IMF tracker, financial forecasts, and valuation modeling. Valuation uses a 2027E P/E multiple and discounts to year-end 2026, while also referencing forecast metrics such as revenue, EBITDA, EPS, dividend yield, free cash flow yield, and CROCI.

Methodology notes

• Valuation methodsP/E target-price approach

  2027E P/E at 12.0x

  The 12-month target price of HK$4.0 is based on 12.0x 2027E P/E and discounted to year-end 2026 using a 10.3% equity cost of capital.

• Factor analysisGS Factor Profile

  Growth, financial returns, valuation multiples, and composite percentile

  Goldman Sachs uses forecast indicators including revenue, EBITDA, EPS, ROE, ROCE, CROCI, and valuation multiples to provide relative market and peer competitive positioning for the stock.

• M&A scenarioM&A Rank

  M&A Rank 3

  An M&A Rank of 3 indicates low probability of a takeover, roughly 0%–15%, and is generally not reflected in the target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China Feihe Ltd. (6186.HK)

  Company covered and investment-rating subject

  Strengths

  Premium new products Jicui/Qicui have upgrade potential; 100% self-sufficiency in milk protein and lactose supports gross margin stability; overseas business has a growth base in Southeast Asia and Canada.

  Weaknesses

  Low visibility of 2026 industry newborn rates; contraction in offline mother-and-baby channel stores; new product scale remains relatively small; sales and marketing spending may pressure operating and net margins.

  Comparison

  Management positions Jicui/Qicui as more competitive against multinational brands compared with Zhuorui; HMO ingredients are expected to attract high-end consumer upgrade demand.

  Risks

  Lower-than-expected newborn rates, intensified competition, slower-than-expected growth in premium categories, industry food safety incidents, or weaker-than-expected policy support.

Key data

• RatingNeutralGoldman Sachs maintains a Neutral rating on China Feihe Ltd.
• 12-month target priceHK$4.0Based on 12.0x 2027E P/E discounted with 10.3% COE.
• Current priceHK$3.41Current price disclosed in the report.
• Implied upside17.3%From the report chart.
• Jan-Feb offline sales trackingdown 15.7% year-on-yearGoldman Sachs IMF tracker shows weakness in offline channels.
• Jan-Feb online sales trackingdown 30% year-on-yearGoldman Sachs IMF tracker shows weakness in online channels.
• 2025 marriage registrationsup 10.8% year-on-yearManagement still sees newborn visibility as low.
• Jicui/Qicui salesRMB70mn monthly sales in Dec 2025Two high-end new products with HMO were launched in Dec 2025.
• Canada businessup 36% year-on-year in 2025Provides the base for future US cross-border e-commerce.
• 2026E revenueRmb18,352.3mnForecast in the report chart.
• 2026E EBITDARmb4,381.5mnForecast in the report chart.
• 2026E EPSRmb0.29Forecast in the report chart.

Impact & implications

In the near term, low birth rates, channel contraction, and competitive intensity limit re-rating potential. Over the medium term, scaling premium new products, product mix upgrading, milk protein/lactose self-sufficiency, online and omnichannel transformation, and overseas expansion are key to improving revenue and profit quality. The Neutral rating reflects a balance between growth drivers and industry pressures.

Risks

• Industry newborn rates coming in higher or lower than expected could affect demand and company sales.
• Competition being stronger or weaker than expected could affect pricing, share, and marketing spend.
• Faster or slower growth than expected in premium segments could affect the impact of product mix upgrading.
• Food safety incidents within the industry could damage consumer confidence.
• Incremental policy support being higher or lower than expected could alter industry demand expectations.

What to watch

• How 2026 newborn rates and the transmission from 2025 marriage registration growth to birth data evolve.
• Whether monthly Jicui/Qicui sales accelerate and the consumer acceptance of HMO premium products.
• The pace of offline mom-and-baby store closures and whether online and omnichannel channels can offset it effectively.
• Post-H1 2026 management updates on OPM/NPM trend trajectory.
• Execution pace of localized products in Southeast Asia, Canada channels, and US cross-border e-commerce.